LncRNA PANDAR is a Novel Prognostic Biomarker in Patients with Cancer: a Meta-Analysis.

BACKGROUND:Mounting evidence from recent studies has revealed the association of lncRNA PANDAR expression levels with outcomes in several types of cancer. However, inconsistent results have also been reported, which rationalized a meta-analysis of available data to analyze the prognostic value of lncRNA PANDAR. METHODS:From inception to May 26, 2018, electronic literature databases including PubMed (medline), the Cochrane Library, ScienceDirect, Springer, ISI Web of Knowledge, Wiley Online library, BioMed Central, and Embase were searched for literature collections. The hazard ratios (HR) with 95% confidence interval (95% CI) were utilized to calculate pooled effect size. RESULTS:A total of 1,132 cancer patients were enrolled in the present meta-analysis to assess the prognostic value of PANDAR in various carcinomas. Promoted PANDAR expression was demonstrated to significantly predict unfavorable OS (HR = 1.77, 95% CI: 1.12 - 2.80, p = 0.014) by the random effects model. According to the stratified analyses and meta-regression results, the heterogeneity of present analysis may be attributed to the differences of cancer resources. Furthermore, over-expression of PANDAR was revealed to be effectively predictive of cancer progression (HR = 1.70, 95% CI: 1.41 - 2.05, p < 0.00001) and LNM (HR = 1.71, 95% CI: 1.39 - 2.10, p < 0.00001). CONCLUSIONS:The present findings indicate that increased PANDAR is associated with poor OS in patients with general carcinomas and may serve as a useful clinical prognostic biomarker.

KEYWORDS: {{ getKeywords(articleDetailText.words) }}